Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EFPIA Picks Holes With EMA's Revised Guidance On Risk Management Plans

This article was originally published in SRA

Executive Summary

The European Federation of Pharmaceutical Industries and Associations has welcomed most of the changes that the European Medicines Agency has proposed making to its guideline on risk management plans (RMPs), saying that the revisions would help remove "several redundancies present in the current version" of the guidance. However, EFPIA has significant concerns over certain other parts of the revised guideline, such as the rewording of certain sections that it believes could be misinterpreted by those enforcing the guideline and create confusion.

You may also be interested in...



EMA Revises Guidance On Risk Management Plans To Address Industry ‘Misunderstandings’

The European Medicines Agency is finalizing changes to its eagerly-awaited guidance on risk management plans, which aims to simplify the submission and maintenance of RMPs by drug companies. The EMA has fine-tuned the document to address some misunderstandings within the industry and is currently deciding on the transition plans for implementing the new requirements.

EU Drug Safety Actions Speeded Up By New Legislation, Says Commission

The European Commission reports that new regulatory tools made available under the revised pharmacovigilance legislation have allowed drug safety issues to be detected and acted upon more rapidly, and that further improvements to the system are in the pipeline.

Global Regulators Issue Advice On Clinical Comparability Of Biosimilar MAbs

The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel